Animal reproductive and developmental toxicity studies have not been conducted with ADSTILADRIN. Independent nonprofit directory of patient assistance programs, copay cards, and charity co-pay foundations. Use the price with your insurance or without — whichever is cheaper. Here are the transparent-pricing directories we recommend checking alongside your insurance formulary. External links go directly to the manufacturer's portal.

Adstiladrin is administered by a healthcare professional directly into the bladder through a catheter, typically once every three months. This gene instructs the body to produce interferon alfa-2b, a protein that helps the immune system fight the cancer cells. The medication works jimi jackson casino by using a modified virus to deliver a copy of a human gene into the cells lining the bladder wall. The manufacturer is not affiliated with, does not endorse, and does not financially support any independent third-party foundations that may be listed. The manufacturer does not review or verify the information on the PrescriberPoint site and makes no representations as to its accuracy or completeness. Hear from Mike, an actual patient who decided with his doctor to stay on ADSTILADRIN for over 6 years.

Do not receive Adstiladrin if you have a sensitivity to interferon alfa or any of its components. ‡Available only for patients who meet eligibility requirements. Your Case Manager will work with your health insurer to determine whether your plan covers the cost of ADSTILADRIN. Eligible patients with commercial insurance maypay as little as $10‡for each ADSTILADRIN prescription

Treatment Discussion Guide

It is specifically indicated for high-risk, Bacillus Calmette-Guerin unresponsive non-muscle invasive bladder cancer with carcinoma in situ, which may or may not include papillary tumors. ADSTILADRIN is a non-replicating adenoviral vector-based gene therapy indicated for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors. ADSTILADRIN is contraindicated in patients with hypersensitivity to interferon alfa or any component of the product. 4 CONTRAINDICATIONS ADSTILADRIN is contraindicated in patients with prior hypersensitivity reactions to interferon alfa or to any component of the product see Description (11) .